PT  - JOURNAL ARTICLE
AU  - Veronica Gonzalez-Pena
AU  - Matthew MacKay
AU  - Iwijn De Vlaminck
AU  - John Easton
AU  - Charles Gawad
TI  - Vast population genetic diversity underlies the treatment dynamics of <em>ETV6-RUNX1</em> acute lymphoblastic leukemia
AID  - 10.1101/117614
DP  - 2017 Jan 01
TA  - bioRxiv
PG  - 117614
4099  - http://biorxiv.org/content/early/2017/03/16/117614.short
4100  - http://biorxiv.org/content/early/2017/03/16/117614.full
AB  - Ensemble-averaged genome profiling of diagnostic samples suggests that acute leukemias harbor few somatic genetic alterations. We used single-cell exome and error-corrected sequencing to survey the genetic diversity underlying ETV6-RUNX1 acute lymphoblastic leukemia (ALL) at high resolution. The survey uncovered a vast range of low-frequency genetic variants that were undetected in conventional bulk assays, including additional clone-specific “driver” RAS mutations. Single-cell exome sequencing revealed APOBEC mutagenesis to be important in disease initiation but not in progression and identified many more mutations per cell than previously found. Using this data, we created a branching model of ETV6-RUNX1 ALL development that recapitulates the genetic features of patients. Exposure of leukemic populations to chemotherapy selected for specific clones in a dose-dependent manner. Together, these data have important implications for understanding the development and treatment response of childhood leukemia, and they provide a framework for using population genetics to deeply interrogate cancer clonal evolution.One-Sentence Summary APOBEC and replication-associated mutagenesis contribute to the development of ETV6-RUNX1 ALL, creating massive leukemic population genetic diversity that results in clonal differences in susceptibilities to chemotherapy.